Screener / SEC EDGAR /CIK 0001579428 /10-K filed Feb 23, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Axsome Therapeutics, Inc. AXSM

Compare with peers Embed
Earnings releases

Latest results release: Nov 2, 2026

8-K item 2.02, exhibit 99

What AXSM's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 2, 2026 · EX-99.1

Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides

Open on SEC

Exhibit 99.1 Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over- year growth

AUVELITY®3Q 2026 net product sales of $207.6 million, representing 53% year- over-year growth

SUNOSI®3Q 2026 net product revenue of $48.2 million, representing 47% year-over- year growth

SYMBRAVO®3Q 2026 net product sales of $3.9 million, representing 88% year-over- year growth

Company to host conference call today at 8:00 AM Eastern Time NEW YORK, November 2, 2026 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the third quarter of 2026 and provided a general business update.

“Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annual run rate. We expect sustained momentum driven by strong underlying demand for Auvelity in major depressive disorder, and continued acceleration of new patient initiations in Alzheimer’s disease agitation,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics. “Our industry-leading neuroscience pipeline continued to advance, leading to multiple anticipated regulatory and clinical trial milestones in the coming quarters. Our commercial and research and development performance positions us to continue to deliver innovation targeting significant unmet needs in brain health, with the potential to improve the lives of millions of patients.”

Total net product revenue was $259.7 million for the third quarter of 2026, representing 52% year-over-year growth. Total net product revenue for the comparable period in 2025 was $171.0 million.

AUVELITY net product sales were $207.6 million for the third quarter of 2026, representing 53% year-over-year growth. AUVELITY net product sales for the comparable period in 2025 were $136.1 million.

SUNOSI net product revenue was $48.2 million for the third quarter of 2026, representing 47% year-over-year growth, which consisted of $38.5 million in net product sales, $1.2 million in royalty revenue associated with SUNOSI sales in out-licensed territories, and $8.5 million in milestone revenue. SUNOSI net product revenue for the comparable period in 2025 was $32.8 million, which consisted of $31.6 million in net product sales and $1.2 million in royalty revenue.

SYMBRAVO net product sales were $3.9 million for the third quarter of 2026, representing 88% year-over-year growth. SYMBRAVO net product sales for the comparable period in 2025 were $2.1 million.

Total cost of revenue was $17.8 million for the third quarter of 2026. Total cost of revenue for the comparable period in 2025 was $11.9 million.

Research and development (R&D) expenses were $50.6 million for the third quarter of 2026, compared to $40.2 million for the comparable period in 2025. The increase primarily reflects costs for the ongoing clinical programs for solriamfetol, AXS-14, and AXS-05. 1 Selling, general, and administrative (SG&A) expenses were $203.1 million for the third quarter of 2026, compared to $150.2 million for the comparable period in 2025. The increase primarily reflects commercialization activities for AUVELITY and SYMBRAVO.

Net loss for the third quarter of 2026 was $12.9 million, or $(0.25) per share, compared to a net loss of $47.2 million, or $(0.94) per share, for the comparable period in 2025. The net loss in the third quarter of 2026 includes $26.4 million in stock-based compensation expense.

Cash and cash equivalents totaled $313.9 million at September 30, 2026, compared to $322.9 million at December 31, 2025.

Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.

AUVELITY is a first‑in‑class oral N-methyl-D-aspartate (NMDA) receptor antagonist and sigma‑1 receptor agonist approved in the U.S. for the treatment of major depressive disorder in adults, and for the treatment of agitation associated with dementia due to Alzheimer’s disease.

Approximately 302,000 total prescriptions were written for AUVELITY in the third quarter of 2026, representing year-over-year and quarter-over-quarter increases of 40% and 14%, respectively. New-to-brand prescriptions, representing new AUVELITY patient starts, increased by 44% year-over-year and 21% quarter-over- quarter.

Third quarter AUVELITY new-to-brand and total prescriptions among patients aged 65 years and older increased by 211% and 101%, respectively, compared to the third quarter of 2025. Third quarter AUVELITY new-to-brand and total prescriptions among patients aged 65 years and older increased by 99% and 43%, respectively, compared to the second quarter of 2026.

Payer coverage for AUVELITY across all channels is currently at approximately 89% of all lives covered. The proportion of lives covered in the commercial and government (Medicare and Medicaid) channels are approximately 82% and 100%, respectively.

SUNOSI is the first and only dopamine and norepinephrine reuptake inhibitor (DNRI) approved for the treatment of excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy.

Approximately 64,400 prescriptions were written for SUNOSI in the U.S. in the third quarter of 2026, a 15% increase compared to the same period in 2025, and a 6% increase compared to the second quarter of 2026.

Payer coverage for SUNOSI across all channels is at approximately 82% of all lives covered, including approximately 97% of commercial lives and 59% of government lives. 2 SYMBRAVO

SYMBRAVO is an oral, rapidly absorbed, multi-mechanistic, COX-2 preferential inhibitor and 5-HT1B/1Dagonist approved in the U.S. for the acute treatment of migraine with or without aura in adults.

Approximately 25,000 prescriptions were written for SYMBRAVO in the third quarter of 2026, a 382% increase compared to the same period in 2025, and a 7% increase compared to the second quarter of 2026.

Payer coverage for SYMBRAVO across all channels is at approximately 57% of all lives covered, including approximately 56% of commercial lives and 57% of government lives.

Axsome is advancing an industry-leading neuroscience pipeline of multiple, innovative product candidates addressing a broad range of serious psychiatric and neurological conditions. Recent and anticipated progress for key pipeline programs is summarized below.

AXS-05 (dextromethorphan-bupropion) is Axsome’s novel, oral, investigational NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor being developed for smoking cessation.

Smoking Cessation: In August 2026, Axsome initiated the SUMMIT study, a Phase 3, randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 for the treatment of smoking cessation. The Company anticipates topline results from the SUMMIT Phase 3 trial in the second half of 2027.

Solriamfetol is Axsome’s DNRI, TAAR1 agonist, and 5-HT1Aagonist being developed for the treatment of attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD) with EDS symptoms, binge eating disorder (BED), and excessive sleepiness associated with shift work disorder (SWD).

Attention Deficit Hyperactivity Disorder: Axsome is conducting the FOCUS-2 and FOCUS-3 Phase 3, randomized, double-blind, placebo-controlled, multicenter trials evaluating the efficacy and safety of solriamfetol as a treatment for children and adolescents in ADHD, respectively. The Company anticipates topline results from both studies in the second half of 2027.

Binge Eating Disorder: Axsome is conducting the ENGAGE study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in BED. Target enrollment in the trial has been reached, and the Company anticipates topline results in the first quarter of 2027.

Shift Work Disorder: Axsome is conducting the SUSTAIN study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial evaluating the efficacy and safety of solriamfetol in SWD in adults. The Company anticipates topline results from SUSTAIN in the second half of 2027.

Major Depressive Disorder: Axsome is conducting the CLARITY study, a Phase 3, double-blind, placebo-controlled, multicenter, randomized withdrawal trial evaluating the efficacy and safety of solriamfetol for the treatment of MDD with EDS symptoms. The Company anticipates completion of enrollment in CLARITY in the first half of 2027. 3 AXS-12

AXS-12 (reboxetine) is Axsome’s novel, oral, investigational, highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator being developed for the treatment of narcolepsy. AXS-12 has been granted FDA Orphan Drug designation for narcolepsy.

Narcolepsy: Axsome’s NDA for AXS-12 for the treatment of cataplexy in narcolepsy is currently under review by the FDA. The PDUFA target action date is May 1, 2027.

AXS-14 (esreboxetine) is Axsome’s novel, oral, investigational, highly selective and potent norepinephrine reuptake inhibitor being developed for the management of fibromyalgia. Esreboxetine is the SS-enantiomer of reboxetine.

Fibromyalgia: Axsome is conducting the FORWARD study, a Phase 3, double-blind, placebo-controlled, multicenter, randomized withdrawal trial evaluating the efficacy and safety of AXS-14 for the management of fibromyalgia. The Company anticipates completion of enrollment in the FORWARD Phase 3 trial in the third quarter of 2027.

AXS-17 is Axsome’s novel oral GABAAreceptor α2,3 subtype-selective positive allosteric modulator (PAM) being developed for the treatment of epilepsy.

Epilepsy: Axsome plans to initiate clinical trials of AXS-17 in epilepsy in the first half of 2027.

AXS-20 (balipodect) is Axsome’s novel oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor being developed for the treatment of schizophrenia.

Schizophrenia: Axsome plans to initiate a pivotal Phase 3 trial of AXS-20 in schizophrenia in the first half of 2027.

AXS-12 for cataplexy in narcolepsy, PDUFA target action (May 1, 2027) 4 Conference Call Information

Axsome will host a conference call and webcast today at 8:00 a.m. Eastern Time to discuss its third quarter 2026 financial results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at axsome.com. A replay of the conference call will be available for approximately 30 days following the live event.

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us atwww.axsome.comand follow us onLinkedInandX. 5 Forward Looking Statements

Certain matters discussed in this press release are “forward-looking statements.” The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward- looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO®products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. 6 Axsome Therapeutics, Inc. Selected Consolidated Financial Data Axsome Therapeutics, Inc. Consolidated Balance Sheets (In thousands, except share and per share amounts)

September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── -Unaudited Assets Current assets: Cash and cash $ 313,859 $ 322,933 equivalents Accounts receivable, 343,114 224,464 net Inventories, 42,579 27,938 net Prepaid and other current 25,084 13,651 assets Total current 724,636 588,986 assets Equipment, 943 562 net Right-of-use asset - 18,284 20,858 operating lease Goodwill 12,042 12,042 Intangible 35,751 40,519 asset, net Non-current inventory and 35,117 26,838 other assets Total assets $ 826,773 $ 689,805 Liabilities and stockholders’ equity Current liabilities: Accounts $ 96,075 $ 65,537 payable Accrued expenses and 331,756 232,853 other current liabilities Operating lease liability, 663 434 current portion Contingent consideratio… 11,225 10,012 current Short-term 70,000 70,000 borrowings Total current 509,719 378,836 liabilities Contingent consideratio… 63,610 77,540 non-current Loan payable, 118,069 117,746 long-term Operating lease 20,748 23,182 liability, long-term Finance lease liability, 9,193 4,206 long-term Total 721,339 601,510 liabilities Stockholders’ equity: Preferred stock, $0.0001 par value per share (10,000,000 — — shares authorized, none issued and outstanding) Common stock, $0.0001 par value per share (150,000,000 shares authorized, 52,576,839 and 5 5 50,882,766 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively) Additional paid-in 1,540,123 1,394,251 capital Accumulated (1,434,694 ) (1,305,961 ) deficit Total stockholders’ 105,434 88,295 equity Total liabilities and $ 826,773 $ 689,805 stockholders’ equity

7 Axsome Therapeutics, Inc. Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share amounts)

Investors: Ashley Dong Senior Director, Investor Relations (929) 687-1614 [email protected] Media: Darren Opland Senior Director, Corporate Communications (929) 837-1065 [email protected] 8

Full text with the tables
                                                                    Exhibit 99.1
 Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides  
                                Business Update                                 
                                                                                
Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-
                                  year growth                                   
                                                                                
  AUVELITY®3Q 2026 net product sales of $207.6 million, representing 53% year-  
                                over-year growth                                
                                                                                
SUNOSI®3Q 2026 net product revenue of $48.2 million, representing 47% year-over-
                                  year growth                                   
                                                                                
SYMBRAVO®3Q 2026 net product sales of $3.9 million, representing 88% year-over- 
                                  year growth                                   
                                                                                
         SUMMIT Phase 3 trial of AXS-05 for smoking cessation initiated         
                                                                                
         Company to host conference call today at 8:00 AM Eastern Time          
NEW YORK, November 2, 2026 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ:
AXSM), a biopharmaceutical company leading a new era in the treatment of central
nervous system (CNS) disorders, today announced financial results for the third
quarter of 2026 and provided a general business update.

“Axsome delivered 52% year-over-year total revenue growth in the third quarter,
surpassing a one-billion-dollar annual run rate. We expect sustained momentum
driven by strong underlying demand for Auvelity in major depressive disorder,
and continued acceleration of new patient initiations in Alzheimer’s disease
agitation,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome
Therapeutics. “Our industry-leading neuroscience pipeline continued to advance,
leading to multiple anticipated regulatory and clinical trial milestones in the
coming quarters. Our commercial and research and development performance
positions us to continue to deliver innovation targeting significant unmet needs
in brain health, with the potential to improve the lives of millions of
patients.”

Third Quarter 2026 Financial Highlights

Total net product revenue was $259.7 million for the third quarter of 2026,
representing 52% year-over-year growth. Total net product revenue for the
comparable period in 2025 was $171.0 million.

AUVELITY net product sales were $207.6 million for the third quarter of 2026,
representing 53% year-over-year growth. AUVELITY net product sales for the
comparable period in 2025 were $136.1 million.

SUNOSI net product revenue was $48.2 million for the third quarter of 2026,
representing 47% year-over-year growth, which consisted of $38.5 million in net
product sales, $1.2 million in royalty revenue associated with SUNOSI sales in
out-licensed territories, and $8.5 million in milestone revenue. SUNOSI net
product revenue for the comparable period in 2025 was $32.8 million, which
consisted of $31.6 million in net product sales and $1.2 million in royalty
revenue.

SYMBRAVO net product sales were $3.9 million for the third quarter of 2026,
representing 88% year-over-year growth. SYMBRAVO net product sales for the
comparable period in 2025 were $2.1 million.

Total cost of revenue was $17.8 million for the third quarter of 2026. Total
cost of revenue for the comparable period in 2025 was $11.9 million.

Research and development (R&D) expenses were $50.6 million for the third quarter
of 2026, compared to $40.2 million for the comparable period in 2025. The
increase primarily reflects costs for the ongoing clinical programs for
solriamfetol, AXS-14, and AXS-05.
                                       1                                        
Selling, general, and administrative (SG&A) expenses were $203.1 million for the
third quarter of 2026, compared to $150.2 million for the comparable period in
2025. The increase primarily reflects commercialization activities for AUVELITY
and SYMBRAVO.

Net loss for the third quarter of 2026 was $12.9 million, or $(0.25) per share,
compared to a net loss of $47.2 million, or $(0.94) per share, for the
comparable period in 2025. The net loss in the third quarter of 2026 includes
$26.4 million in stock-based compensation expense.

Cash and cash equivalents totaled $313.9 million at September 30, 2026, compared
to $322.9 million at December 31, 2025.

Shares of common stock outstanding were 52,576,839 at September 30, 2026.

Financial Guidance

Axsome believes that its current cash is sufficient to fund anticipated
operations into cash flow positivity, based on the current operating plan.

Commercial Highlights

AUVELITY

AUVELITY is a first‑in‑class oral N-methyl-D-aspartate (NMDA) receptor
antagonist and sigma‑1 receptor agonist approved in the U.S. for the treatment
of major depressive disorder in adults, and for the treatment of agitation
associated with dementia due to Alzheimer’s disease.

Approximately 302,000 total prescriptions were written for AUVELITY in the third
quarter of 2026, representing year-over-year and quarter-over-quarter increases
of 40% and 14%, respectively. New-to-brand prescriptions, representing new
AUVELITY patient starts, increased by 44% year-over-year and 21% quarter-over-
quarter.

Third quarter AUVELITY new-to-brand and total prescriptions among patients aged
65 years and older increased by 211% and 101%, respectively, compared to the
third quarter of 2025. Third quarter AUVELITY new-to-brand and total
prescriptions among patients aged 65 years and older increased by 99% and 43%,
respectively, compared to the second quarter of 2026.

Payer coverage for AUVELITY across all channels is currently at approximately
89% of all lives covered. The proportion of lives covered in the commercial and
government (Medicare and Medicaid) channels are approximately 82% and 100%,
respectively.

SUNOSI

SUNOSI is the first and only dopamine and norepinephrine reuptake inhibitor
(DNRI) approved for the treatment of excessive daytime sleepiness associated
with obstructive sleep apnea or narcolepsy.

Approximately 64,400 prescriptions were written for SUNOSI in the U.S. in the
third quarter of 2026, a 15% increase compared to the same period in 2025, and a
6% increase compared to the second quarter of 2026.

Payer coverage for SUNOSI across all channels is at approximately 82% of all
lives covered, including approximately 97% of commercial lives and 59% of
government lives.
                                       2                                        
SYMBRAVO

SYMBRAVO is an oral, rapidly absorbed, multi-mechanistic, COX-2 preferential
inhibitor and 5-HT1B/1Dagonist approved in the U.S. for the acute treatment of
migraine with or without aura in adults.

Approximately 25,000 prescriptions were written for SYMBRAVO in the third
quarter of 2026, a 382% increase compared to the same period in 2025, and a 7%
increase compared to the second quarter of 2026.

Payer coverage for SYMBRAVO across all channels is at approximately 57% of all
lives covered, including approximately 56% of commercial lives and 57% of
government lives.

Development Pipeline

Axsome is advancing an industry-leading neuroscience pipeline of multiple,
innovative product candidates addressing a broad range of serious psychiatric
and neurological conditions. Recent and anticipated progress for key pipeline
programs is summarized below.

AXS-05

AXS-05 (dextromethorphan-bupropion) is Axsome’s novel, oral, investigational
NMDA receptor antagonist, sigma-1 agonist, and aminoketone CYP2D6 inhibitor
being developed for smoking cessation.

Smoking Cessation: In August 2026, Axsome initiated the SUMMIT study, a Phase 3,
randomized, double-blind, active- and placebo-controlled, multicenter trial to
assess the efficacy and safety of AXS-05 for the treatment of smoking cessation.
The Company anticipates topline results from the SUMMIT Phase 3 trial in the
second half of 2027.

Solriamfetol

Solriamfetol is Axsome’s DNRI, TAAR1 agonist, and 5-HT1Aagonist being developed
for the treatment of attention deficit hyperactivity disorder (ADHD), major
depressive disorder (MDD) with EDS symptoms, binge eating disorder (BED), and
excessive sleepiness associated with shift work disorder (SWD).

Attention Deficit Hyperactivity Disorder: Axsome is conducting the FOCUS-2 and
FOCUS-3 Phase 3, randomized, double-blind, placebo-controlled, multicenter
trials evaluating the efficacy and safety of solriamfetol as a treatment for
children and adolescents in ADHD, respectively. The Company anticipates topline
results from both studies in the second half of 2027.

Binge Eating Disorder: Axsome is conducting the ENGAGE study, a Phase 3,
randomized, double-blind, placebo-controlled, multicenter trial evaluating the
efficacy and safety of solriamfetol in BED. Target enrollment in the trial has
been reached, and the Company anticipates topline results in the first quarter
of 2027.

Shift Work Disorder: Axsome is conducting the SUSTAIN study, a Phase 3,
randomized, double-blind, placebo-controlled, multicenter trial evaluating the
efficacy and safety of solriamfetol in SWD in adults. The Company anticipates
topline results from SUSTAIN in the second half of 2027.

Major Depressive Disorder: Axsome is conducting the CLARITY study, a Phase 3,
double-blind, placebo-controlled, multicenter, randomized withdrawal trial
evaluating the efficacy and safety of solriamfetol for the treatment of MDD with
EDS symptoms. The Company anticipates completion of enrollment in CLARITY in the
first half of 2027.
                                       3                                        
AXS-12

AXS-12 (reboxetine) is Axsome’s novel, oral, investigational, highly selective
and potent norepinephrine reuptake inhibitor and cortical dopamine modulator
being developed for the treatment of narcolepsy. AXS-12 has been granted FDA
Orphan Drug designation for narcolepsy.

Narcolepsy: Axsome’s NDA for AXS-12 for the treatment of cataplexy in narcolepsy
is currently under review by the FDA. The PDUFA target action date is May 1,
2027.

AXS-14

AXS-14 (esreboxetine) is Axsome’s novel, oral, investigational, highly selective
and potent norepinephrine reuptake inhibitor being developed for the management
of fibromyalgia. Esreboxetine is the SS-enantiomer of reboxetine.

Fibromyalgia: Axsome is conducting the FORWARD study, a Phase 3, double-blind,
placebo-controlled, multicenter, randomized withdrawal trial evaluating the
efficacy and safety of AXS-14 for the management of fibromyalgia. The Company
anticipates completion of enrollment in the FORWARD Phase 3 trial in the third
quarter of 2027.

AXS-17

AXS-17 is Axsome’s novel oral GABAAreceptor α2,3 subtype-selective positive
allosteric modulator (PAM) being developed for the treatment of epilepsy.

Epilepsy: Axsome plans to initiate clinical trials of AXS-17 in epilepsy in the
first half of 2027.

AXS-20

AXS-20 (balipodect) is Axsome’s novel oral, potent, and selective
phosphodiesterase 10A (PDE10A) inhibitor being developed for the treatment of
schizophrenia.

Schizophrenia: Axsome plans to initiate a pivotal Phase 3 trial of AXS-20 in
schizophrenia in the first half of 2027.

Anticipated Milestones

Clinical Trial Initiations:

Phase 1B trial of AXS-17 in epilepsy (1H 2027)

Phase 3 trial of AXS-20 in schizophrenia (1H 2027)

Clinical Trial Topline Results:

Phase 3 ENGAGE trial of solriamfetol in binge eating disorder (1Q 2027)

Phase 3 SUSTAIN trial of solriamfetol in shift work disorder (2H 2027)

Phase 3 FOCUS-2 trial of solriamfetol in children with ADHD (2H 2027)

Phase 3 FOCUS-3 trial of solriamfetol in adolescents with ADHD (2H 2027)

Phase 3 SUMMIT trial of AXS-05 in smoking cessation (2H 2027)

Regulatory and Commercial:

AXS-12 for cataplexy in narcolepsy, PDUFA target action (May 1, 2027)
                                       4                                        
Conference Call Information

Axsome will host a conference call and webcast today at 8:00 a.m. Eastern Time
to discuss its third quarter 2026 financial results and provide a business
update. To participate in the live conference call, please dial (877) 405-1239
(toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the
conference call can be accessed on the “Webcasts & Presentations” page of the
“Investors” section of the Company’s website at axsome.com. A replay of the
conference call will be available for approximately 30 days following the live
event.

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company leading a new era in the
treatment of central nervous system (CNS) conditions. We deliver scientific
breakthroughs by identifying critical gaps in care and develop differentiated
products with a focus on novel mechanisms of action that enable meaningful
advancements in patient outcomes. Our industry-leading neuroscience portfolio
includes FDA-approved treatments for major depressive disorder, agitation
associated with dementia due to Alzheimer’s disease, excessive daytime
sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine,
as well as multiple novel product candidates addressing a broad range of serious
neurological and psychiatric conditions that impact over 150 million people in
the United States. Together, we are on a mission to solve some of the brain’s
biggest problems so patients and their loved ones can flourish. For more
information, please visit us atwww.axsome.comand follow us onLinkedInandX.
                                       5                                        
Forward Looking Statements

Certain matters discussed in this press release are “forward-looking
statements.” The Company may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words
that convey uncertainty of future events or outcomes to identify these forward-
looking statements. In particular, the Company’s statements regarding trends and
potential future results are examples of such forward-looking statements. The
forward-looking statements include risks and uncertainties, including, but not
limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and
SYMBRAVO®products and the success of the Company’s efforts to obtain any
additional indication(s) with respect to solriamfetol and/or AXS-05; the
Company’s ability to maintain and expand payer coverage; the success, timing and
cost of the Company’s ongoing clinical trials and anticipated clinical trials
for the Company’s current product candidates, including statements regarding the
timing of initiation, pace of enrollment and completion of the trials (including
the Company’s ability to fully fund the Company’s disclosed clinical trials,
which assumes no material changes to the Company’s currently projected revenues
or expenses), futility analyses and receipt of interim results, which are not
necessarily indicative of the final results of the Company’s ongoing clinical
trials, and/or data readouts, and the number or type of studies or nature of
results necessary to support the filing of a new drug application (“NDA”) for
any of the Company’s current product candidates; the Company’s ability to fund
additional clinical trials to continue the advancement of the Company’s product
candidates; the timing of and the Company’s ability to obtain and maintain U.S.
Food and Drug Administration (“FDA”) or other regulatory authority approval of,
or other action with respect to, the Company’s product candidates, including
statements regarding the timing of any NDA submission; the Company’s ability to
successfully defend its intellectual property or obtain the necessary licenses
at a cost acceptable to the Company, if at all; the Company’s ability to
successfully resolve any intellectual property litigation, and even if such
disputes are settled, whether the applicable federal agencies will approve of
such settlements; the successful implementation of the Company’s research and
development programs and collaborations; the success of the Company’s license
agreements; the acceptance by the market of the Company’s products and product
candidates, if approved; the Company’s anticipated capital requirements,
including the amount of capital required for the commercialization of SUNOSI,
AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other
product candidates, if approved, and the potential impact on the Company’s
anticipated cash runway; the Company’s ability to convert sales to recognized
revenue and maintain a favorable gross to net sales; unforeseen circumstances or
other disruptions to normal business operations arising from or related to
domestic political climate, geo-political conflicts or a global pandemic and
other factors, including general economic conditions and regulatory
developments, not within the Company’s control. The factors discussed herein
could cause actual results and developments to be materially different from
those expressed in or implied by such statements. The forward-looking statements
are made only as of the date of this press release and the Company undertakes no
obligation to publicly update such forward-looking statements to reflect
subsequent events or circumstances.
                                       6                                        
Axsome Therapeutics, Inc. Selected Consolidated Financial Data Axsome
Therapeutics, Inc. Consolidated Balance Sheets (In thousands, except share and
per share amounts)
                                                                                
                   September 30,                   December 31,                 
                   2026                            2025                         
 ────────────────────────────────────────────────────────────────────────────── 
                   -Unaudited                                                   
  Assets                                                                        
  Current                                                                       
  assets:                                                                       
  Cash and cash    $                 313,859       $                322,933     
  equivalents                                                                   
  Accounts                                                                      
  receivable,                        343,114                        224,464     
  net                                                                           
  Inventories,                        42,579                         27,938     
  net                                                                           
  Prepaid and                                                                   
  other current                       25,084                         13,651     
  assets                                                                        
  Total current                      724,636                        588,986     
  assets                                                                        
  Equipment,                             943                            562     
  net                                                                           
  Right-of-use                                                                  
  asset -                             18,284                         20,858     
  operating                                                                     
  lease                                                                         
  Goodwill                            12,042                         12,042     
  Intangible                          35,751                         40,519     
  asset, net                                                                    
  Non-current                                                                   
  inventory and                       35,117                         26,838     
  other assets                                                                  
  Total assets     $                 826,773       $                689,805     
  Liabilities                                                                   
  and                                                                           
  stockholders’                                                                 
  equity                                                                        
  Current                                                                       
  liabilities:                                                                  
  Accounts         $                  96,075       $                 65,537     
  payable                                                                       
  Accrued                                                                       
  expenses and                       331,756                        232,853     
  other current                                                                 
  liabilities                                                                   
  Operating                                                                     
  lease                                                                         
  liability,                             663                            434     
  current                                                                       
  portion                                                                       
  Contingent                                                                    
  consideratio…                       11,225                         10,012     
  current                                                                       
  Short-term                          70,000                         70,000     
  borrowings                                                                    
  Total current                      509,719                        378,836     
  liabilities                                                                   
  Contingent                                                                    
  consideratio…                       63,610                         77,540     
  non-current                                                                   
  Loan payable,                      118,069                        117,746     
  long-term                                                                     
  Operating                                                                     
  lease                               20,748                         23,182     
  liability,                                                                    
  long-term                                                                     
  Finance lease                                                                 
  liability,                           9,193                          4,206     
  long-term                                                                     
  Total                              721,339                        601,510     
  liabilities                                                                   
  Stockholders’                                                                 
  equity:                                                                       
  Preferred                                                                     
  stock,                                                                        
  $0.0001 par                                                                   
  value per                                                                     
  share                                                                         
  (10,000,000                              —                              —     
  shares                                                                        
  authorized,                                                                   
  none issued                                                                   
  and                                                                           
  outstanding)                                                                  
  Common stock,                                                                 
  $0.0001 par                                                                   
  value per                                                                     
  share                                                                         
  (150,000,000                                                                  
  shares                                                                        
  authorized,                                                                   
  52,576,839                                                                    
  and                                      5                              5     
  50,882,766                                                                    
  shares issued                                                                 
  and                                                                           
  outstanding                                                                   
  at September                                                                  
  30, 2026                                                                      
  and December                                                                  
  31, 2025,                                                                     
  respectively)                                                                 
  Additional                                                                    
  paid-in                          1,540,123                      1,394,251     
  capital                                                                       
  Accumulated                     (1,434,694  )                  (1,305,961  )  
  deficit                                                                       
  Total                                                                         
  stockholders’                      105,434                         88,295     
  equity                                                                        
  Total                                                                         
  liabilities                                                                   
  and              $                 826,773       $                689,805     
  stockholders’                                                                 
  equity                                                                        
                                                                                
                                       7                                        
Axsome Therapeutics, Inc. Consolidated Statements of Operations (Unaudited) (In
thousands, except share and per share amounts)
                                                                                
          Three                               Nine                              
          mont…                               mont…                             
          ended                               ended                             
          Sept…                               Sept…                             
          30,                                 30,                               
  Rev…    2026               2025             2026              2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Pro…                                                                          
  sal…    $      249,…       $     169…       $      655…       $     439,…     
  net                                                                           
  Roy…                                                                          
  rev…                                                                          
  and            9,740             1,2…              13,…             3,396     
  mil…                                                                          
  rev…                                                                          
  Tot…           259,…             170…              669…             442,…     
  rev…                                                                          
  Ope…                                                                          
  exp…                                                                          
  Cost                                                                          
  of                                                                            
  rev…                                                                          
  (ex…           17,8…             11,…              46,…             35,1…     
  amo…                                                                          
  and                                                                           
  dep…                                                                          
  Res…                                                                          
  and            50,6…             40,…              149…             134,…     
  dev…                                                                          
  Sel…                                                                          
  gen…           203,…             150…              596…             401,…     
  and                                                                           
  adm…                                                                          
  Loss                                                                          
  (Ga…                                                                          
  in                                                                            
  fair           (2,3…  )          13,…              (3,…  )          6,595     
  val…                                                                          
  of                                                                            
  con…                                                                          
  con…                                                                          
  Int…                                                                          
  ass…           1,607             1,6…              4,7…             4,768     
  amo…                                                                          
  Tot…                                                                          
  ope…           270,…             217…              793…             582,…     
  exp…                                                                          
  Loss                                                                          
  from           (11,…  )          (46…  )           (12…  )          (139…  )  
  ope…                                                                          
  Int…                                                                          
  exp…           (1,7…  )          (1,…  )           (4,…  )          (5,3…  )  
  net                                                                           
  Loss                                                                          
  on                 —                —                 —             (10,…  )  
  debt                                                                          
  ext…                                                                          
  Loss                                                                          
  bef…           (12,…  )          (47…  )           (12…  )          (155…  )  
  inc…                                                                          
  tax…                                                                          
  Inc…                                                                          
  tax              (88  )             —              (216  )            960     
  ben…                                                                          
  (ex…                                                                          
  Net     $      (12,…  )    $     (47…  )    $      (12…  )    $     (154…  )  
  loss                                                                          
  Net                                                                           
  loss                                                                          
  per                                                                           
  com…    $      (0.25  )    $     (0.…  )    $      (2.…  )    $     (3.13  )  
  sha…                                                                          
  bas…                                                                          
  and                                                                           
  dil…                                                                          
  Wei…                                                                          
  ave…                                                                          
  com…                                                                          
  sha…           52,4…             50,…              51,…             49,4…     
  out…                                                                          
  bas…                                                                          
  and                                                                           
  dil…                                                                          
                                                                                
Investors: Ashley Dong Senior Director, Investor Relations (929) 687-1614
[email protected] Media: Darren Opland Senior Director, Corporate Communications
(929) 837-1065 [email protected]
                                       8                                        

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AXSM/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.